TMO

Thermo Fisher ScientificB

NYSE / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

20%

Probability

Target price

$787.50

+63.4% vs current

Most likely

Base case

60%

Probability

Target price

$638.08

+32.4% vs current

B-

Bear case

20%

Probability

Target price

$510.00

+5.8% vs current

AI sentiment snapshot

Latest data as of 2026-01-30

AI commentary

Market sentiment is cautiously constructive after a strong Q4 2025 print, with analysts’ median targets above the current anchor supporting upside expectations [#SERP-8]. However, investor focus remains on instrument order cadence and integration execution, which injects near-term uncertainty [#SERP-2]. Overall tone is mixed‑positive with upside skew if demand and margins hold [#SERP-1].

RankAlpha Sentiment AI - 2026-01-30

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-04-30eventNext quarterly earnings (estimated)Medium impact

Next quarterly report (estimated) — market will focus on revenue, adjusted EPS and margin trajectory after Thermo Fisher's Q4 2025 beat; date estimated by short-window assumption [#SERP-8].

2026-04-30catalystLife-sciences demand rebound / instrument order flowHigh impact

Sustained recovery in instrument and consumables orders could materially lift near-term revenue growth; consensus commentary highlights sensitivity to life-sciences end-market demand [#SERP-1].

2027-01-30catalystM&A / integration-driven upsideHigh impact

Strategic acquisitions and successful integration could drive outsized longer-term revenue and margin expansion; timing extended (assumed one-year horizon).

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-01-30 • Updated nightlySource: Internal modelMethodology